Beam Therapeutics Inc. (BEAM)

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines through the use of base editing technology. The company was founded in 2017 by David R. Liu, Feng Zhang, and J. Keith Joung, who are pioneers in the field of gene editing and synthetic biology. Beam’s innovative approach allows for precise edits to single bases in the genome, offering potential treatments for a variety of genetic and other serious diseases. Headquartered in Cambridge, Massachusetts, Beam emphasizes groundbreaking research to push the boundaries of what is possible in genetic therapy. As of recent reports, Beam has been steadily growing and expanding its pipeline and collaborations, although specific financial data such as recent revenue figures might fluctuate and should be checked for the latest information. The company is publicly traded on the NASDAQ under the ticker symbol “BEAM.” Beam Therapeutics aspires to transform the lives of patients by advancing a new class of genetic medicines with the potential for lasting therapeutic impact.